stockrow
Friday 6 November 2026
Export MBOT’s income statement to Excel — free account
Microbot Medical Inc.
MBOT Healthcare Medical Devices
- Revenue
- +1,047.6%
- EPS
- +20.0%
- Free cash flow
- −98.7%
Quarter to June 2026, against a year earlier
1.06
0.01
−0.93%
Follow MBOT
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | 0 | — | 1 | 6 | 23 | +321.2% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | (166.30) | 0.0 pt | ||||||
| EBT | (10) | (8) | (7) | (7) | (9) | (11) | (13) | (11) | (11) | (13) | (16) | +3.5% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (3,955.22) | 0.0 pt | ||||||
| Net income | (10) | (8) | (7) | (7) | (9) | (11) | (13) | (11) | (11) | (13) | (16) | +3.5% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | n/m | |||||
| Earnings | (10.14) | (3.52) | (2.41) | (1.70) | (1.29) | (1.59) | (1.81) | (1.05) | (0.73) | (0.29) | (0.24) | (32.6%) | ||||||
| Cash flow | (0.82) | (2.23) | (1.83) | (1.51) | (1.02) | (1.32) | (1.59) | (0.84) | (0.56) | (0.28) | (0.26) | (11.1%) | ||||||
| Capex | (0.03) | (0.03) | (0.08) | 0.01 | (0.01) | (0.01) | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | (28.4%) | ||||||
| Free cash flow | (0.85) | (2.26) | (1.91) | (1.50) | (1.03) | (1.33) | (1.60) | (0.84) | (0.57) | (0.29) | (0.27) | (11.4%) | ||||||
| Book value | 2.30 | 4.80 | 0.46 | 7.39 | 3.42 | 2.02 | 1.00 | 0.44 | 0.23 | 1.69 | 1.03 | (3.4%) | ||||||
| Shares, m | 1 | 2 | 3 | 4 | 7 | 7 | 7 | 10 | 16 | 46 | 57 | +53.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (1) | (5) | (5) | (6) | (7) | (9) | (12) | (9) | (9) | (13) | (18) | +36.6% | |||||
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | +10.2% | ||||||
| Free cash flow | (1) | (5) | (6) | (6) | (7) | (9) | (12) | (9) | (9) | (13) | (18) | +36.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 3 | 10 | 1 | 31 | 24 | 14 | 7 | 4 | 3 | 76 | 68 | +46.0% | |||||
| Net debt | (3) | (11) | (5) | (36) | (25) | (16) | (8) | (6) | (6) | (79) | (68) | +45.8% | ||||||
| Shareholders’ equity | 2 | 10 | 1 | 32 | 24 | 14 | 7 | 5 | 4 | 78 | 69 | +48.6% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (292.99) | (83.50) | (84.86) | (33.54) | (28.92) | (52.56) | (100.12) | (120.24) | (159.40) | (30.01) | (30.68) | +263.0 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (850.51) | 0.0 pt | ||||||
| ROE | (558.34) | (94.90) | (123.11) | (44.09) | (32.84) | (58.48) | (121.53) | (182.19) | (284.97) | (32.42) | (32.91) | +525.9 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 7 | 7 | 9 | 9 | 2 | 3 | 21 | 22 | 21 | 43 | — | +22.3% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2014 · latest quarter Jun 2026
Microbot Medical Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ZOMDF Zomedica Corp. | $95.4M | — (loss-making) | — (loss-making) | +22.29% (above 0%: growing) | n/m | +32.51% (above 0%: growing) | 61.06% | (34.60%) | Compare |
| NYXH Nyxoah SA | $82.6M | — (loss-making) | — (loss-making) | +486.62% (above 0%: growing) | n/m | +4.01% (above 0%: growing) | 59.73% | (268.25%) | Compare |
| SERA Sera Prognostics, Inc. | $82.1M | — (loss-making) | — (loss-making) | +162.50% (above 0%: growing) | n/m | −12.79% (below 0%: shrinking) | 0.00% | (21,159.52%) | Compare |
| ECOR electroCore, Inc. | $79.3M | — (loss-making) | — (loss-making) | +11.52% (above 0%: growing) | n/m | −69.10% (below 0%: shrinking) | 88.47% | (16.06%) | Compare |
| LUCD Lucid Diagnostics Inc. | $79.3M | — (loss-making) | — (loss-making) | +26.74% (above 0%: growing) | n/m | −7.04% (below 0%: shrinking) | 1.97% | (868.45%) | Compare |
| OM Outset Medical, Inc. | $77.0M | — (loss-making) | — (loss-making) | +14.15% (above 0%: growing) | n/m | −61.85% (below 0%: shrinking) | 40.69% | (36.52%) | Compare |
| HYPR Hyperfine, Inc. | $72.7M | — (loss-making) | — (loss-making) | +44.81% (above 0%: growing) | n/m | +13.43% (above 0%: growing) | 50.72% | (216.93%) | Compare |
| MBOT Microbot Medical Inc. | $71.9M | — (loss-making) | — | +1,047.62% (above 0%: growing) | n/m | −98.72% (below 0%: shrinking) | (266.80%) | (2,567.63%) | |
| LNSR LENSAR, Inc. | $67.6M | 3.9× | 6.9× | +18.37% (above 0%: growing) | n/m | +96.81% (above 0%: growing) | 59.27% | 12.94% | Compare |
| Median of peers | $79.3M | — | — | +24.52% | — | −1.52% | 54.99% | (126.72%) |
Pay and ownership Proxy statement filed 29 April 2025
Ownership
Directors and executive officers, together
4.74%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement